Is NCT04926467 recruiting in Dallas, TX?

Yes, NCT04926467 is currently recruiting participants at its Dallas, TX location. This pancreatic adenocarcinoma clinical trial is actively enrolling qualified participants.

How do I join the pancreatic adenocarcinoma clinical trial in Dallas?

To join this clinical trial in Dallas, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Dallas clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Pancreatic Adenocarcinoma Clinical Trial in Dallas, TX

About This Pancreatic Adenocarcinoma Study in Dallas

Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed.

Sponsor: Baylor Research Institute

Who Can Participate

Inclusion Criteria

A patient will be eligible for inclusion in this study if he or she meets all of the following criteria:

18 years of age or older

Histologically or Cytologically confirmed pancreatic ductal adenocarcinoma. Mixed subtypes of adenocarcinoma are acceptable as long as majority of cells are ductal adenocarcinoma.

Resectable, locally advanced or potentially resectable pancreatic adenocarcinoma

American Joint Committee on Cancer (AJCC) Stage I-III Pancreatic carcinoma.

Patient has Eastern Cooperative Oncology Group( ECOG ) Performance Status 0 to 1

Serum albumin ≥2.0 g/dL.

Adequate hematologic function as defined by:

Absolute neutrophil count (ANC) ≥1500/mm3;

Platelets ≥70,000 x 10\^3/µl;

Hemoglobin ≥9 g/dL (in the absence of red blood transfusion).

Adequate liver function, as defined by:

Serum total bilirubin ≤2 x ULN mg/dL, prior to initiation of treatment.

ALT (SGPT) and AST (SGOT) ≤2.5 x upper limit of normal (ULN).

Adequate renal function, as defined by serum creatinine≤ 1.5 x ULN, or creatinine clearance ≥50 mL/min

Women of child bearing potential and men must agree to use contraception throughout the study and for one month after the last anakinra administration.

Subjects must understand and sign the informed consent form

Patients must be accessible for treatment and follow-up.

Exclusion Criteria

A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:

\<18 years of age

History of organ transplant.

Patients with islet cell neoplasms

Patients with stage IV pancreatic carcinoma

Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy

Known active infection with hepatitis B or hepatitis C

Presence of clinically significant cirrhosis as determined by the investigator

Known HIV positive status.

Current, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.

Major surgery or vascular device placement within 2 weeks prior to Day 1 of treatment in study

Prior chemotherapy or radiation for pancreatic cancer

History of allergy or hypersensitivity to the study drugs

Patient is enrolled in any outside therapeutic clinical protocol or investigational trial with an investigational drug within 5 half-lives prior to Study ID assignment

Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor

Other malignancy within five years(except cutaneous, non-melanoma malignancies or cervical carcinoma in site), unless the probability of recurrence of the prior malignancy is \<5% as determined by the Principal Investigator based on available information.

Significant cardiac disease (uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias) within the last six months.

Other severe and/or uncontrolled medical conditions (e.g: prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation) or other conditions deemed by investigator as unsuitable for participation/enrollment

Peripheral sensory neuropathy \> or equal to grade 2 at baseline

Abnormal liver function tests as follows:

Total bilirubin of \> 2 x ULN

AST or ALT \> 5x ULN

Serum albumin ˂ 2.0 g/dL.

Abnormal hematologic function as follows :

Absolute neutrophil count (ANC) ˂ 1500/mm3;

Platelets ˂ 70,000 x 10\^3/µl;

Hemoglobin ˂ 9 g/dL (in the absence of red blood transfusion).

Pregnant or nursing women

No signed Informed consent form

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT04926467) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Adenocarcinoma Treatment Options in Dallas, TX

If you're searching for pancreatic adenocarcinoma treatment options in Dallas, TX, this clinical trial (NCT04926467) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

Pancreatic Adenocarcinoma Clinical Trial in Dallas, TX

Expert Care in Dallas

IRB Approved

No-Cost Care

Apply for This Dallas Location

Why Participate?

Simple Process